Initial public offerings scheduled to debut next week

Question of the Day

Should Congress make English the official language of the U.S.?

View results

NEW YORK (AP) - The following is a list of initial public offerings planned for the coming week. Sources include Renaissance Capital, Greenwich, CT (www.renaissancecapital.com) and SEC filings.

Week of February 3

Argos Therapeutics Inc. - Durham, N.C., 4.3 million shares, priced $13 to $15, managed by Piper Jaffray, Stifel, and JMP Securities. Proposed Nasdaq symbol ARGS. Business: Developing immunotherapies for the treatment of cancer and HIV. Previously filed and withdrew in 2012.

Auspex Pharmaceuticals Inc. - San Diego, 5.5 million shares, priced $10 to $12, managed by Stifel and BMO Capital Markets. Proposed Nasdaq symbol ASPX. Business: Clinical-stage biotech developing treatments for orphan diseases.

Biocept Inc. - San Diego, 1.8 million shares, priced $10 to $12, managed by Aegis Capital. Proposed Nasdaq symbol BIOC. Business: Develops and markets cancer diagnostic tests.

Continental Building Products Inc. - Reston, Va., 13.2 million shares, priced $16 to $18, managed by Citigroup, Credit Suisse, and Barclays. Proposed NYSE symbol CBPX. Business: Manufactures and sells drywall in the eastern U.S. and Canada.

Egalet Corp. - Malvern, Pa., 3.5 million shares, priced $11 to $13, managed by Stifel and JMP Securities. Proposed Nasdaq symbol EGLT. Business: Developing abuse-deterrent oral products for the treatment of pain.

Eleven Biotherapeutics Inc. - Cambridge, Mass., 4.3 million shares, priced $13 to 415, managed by Citigroup, Cowen & Co., and Leerink Partners. Proposed Nasdaq symbol EBIO. Business: Clinical-stage biotech developing protein therapeutics to treat eye diseases.

Genocea Bioscience Inc. - Cambridge, Mass., 5.5 million shares, priced $12 to $14, managed by Citigroup and Cowen & Co. Proposed Nasdaq symbol GNCA. Business: Develops novel vaccines for infectious diseases through T cell immune responses.

GeoPark Ltd. - Santiago, Chile, 20 million shares, priced $8 to $10, managed by J.P. Morgan, BTG Pactual, and Itau BBA. Proposed NYSE symbol GPRK. Business: Oil and natural gas exploration and production company operating in Chile, Colombia, and Brazil. Trades in Santiago and London.

Ladder Capital Corp. - New York, 13.3 million shares, priced $16 to $18, managed by Deutsche Bank, Citigroup, and Wells Fargo. Proposed NYSE symbol LADR. Business: Commercial real estate mortgage origination and finance company.

NephroGenex Inc. - Research Triangle Park, N.C., 3.1 million shares, priced $12 to $14, managed by Aegis Capital. Proposed Nasdaq symbol NRX. Business: Clinical-stage biotech developing treatments for kidney disease.

Revance Therapeutics Inc. - Newark, Calif., 5 million shares, priced $14 to $16, managed by Cowen & Co., and Piper Jaffray. Proposed Nasdaq symbol RVNC. Business: Clinical-stage biotech developing enhanced formulations of botulinum toxin (Botox).

UniQure N.V. - Amsterdam, Netherlands, 4.6 million ordinary shares, priced $13 to $15, managed by Jefferies, Leerink Partners, and Piper Jaffray. Proposed Nasdaq symbol QURE. Business: Develops gene therapies for the treatment of orphan diseases.

Copyright 2014 The Associated Press. All rights reserved. This material may not be published, broadcast, rewritten or redistributed.

Comments
blog comments powered by Disqus
TWT Video Picks